Ulla's primary expertise is on economic evaluation of health care interventions, in particular vaccines. Ulla has undertaken economic evaluations on numerous vaccines, primarily in low- and middle-income countries. She has considerable experience in treatment cost data collection, health related quality of life measurements and development of cost-effectiveness models. During 2006-2009, Ulla was Director of cost-effectiveness for the Hib Initiative, a project funded by the GAVI Alliance to expedite decision making about Haemophilus influenzaetype b (Hib) vaccine in GAVI eligible countries. In addition to the work on vaccines, Ulla is also involved in economic evaluations of interventions to control and treat obesity, diabetes, tuberculosis and eye conditions.